Latest Cancer TreatmentsDr. Mohammadreza Dabiri
Dr. Mohammadreza Dabiriفارسی
Treatment regimen

Docetaxel in metastatic prostate cancer

Castration-resistant (TAX 327) and hormone-sensitive (CHAARTED)

Updated: 28 October 20261 min read3 references

Summary for doctors

  • Castration-resistant: with prednisone for up to 10 cycles [1].
  • High-volume hormone-sensitive: 6 cycles with hormone therapy [2].
  • Hormone therapy (ADT) continues in all cases.

Dose and schedule

Docetaxel (castration-resistant)

Metastatic castration-resistant prostate cancerEach drug’s schedule in the table

Metastatic castration-resistant prostate cancer

DrugDoseRouteSchedule
Docetaxel75 mg/m²IV over 1 hourDay 1
Prednisone5 mg twice a dayOralDaily
Cycle schedule
Every 21 days
Duration
Up to 10 cycles

As in TAX 327 [1].

Dose source: [3].

Evidence: TAX 327 (2004)

Docetaxel (hormone-sensitive)

Metastatic hormone-sensitive prostate cancer, especially high-volumeEach drug’s schedule in the table

Metastatic hormone-sensitive prostate cancer, especially high-volume

DrugDoseRouteSchedule
Docetaxel75 mg/m²IVDay 1
Hormone therapy (ADT)Continuous
Cycle schedule
Every 21 days
Duration
6 cycles

As in CHAARTED [2]. Today it is usually given with a newer hormonal tablet (darolutamide or abiraterone).

Dose source: [3].

Evidence: CHAARTED (E3805) (2015)

Doses follow the trial protocol, guideline or official drug label (source given in the notes of each regimen). Before prescribing, check blood counts, renal and hepatic function, drug interactions and the patient’s condition, and adjust the dose according to the drug label.

Premedication and supportive care

  • Docetaxel premedication: dexamethasone 8 mg at 12, 3 and 1 hours before the infusion (with daily prednisone).
  • Antiemetics: low emetogenicity.
  • G-CSF in older patients or after febrile neutropenia.

Monitoring and dose adjustment

  • Blood counts, liver enzymes and PSA before each cycle; ANC 1500 or more.
  • Neuropathy, fluid retention, nail changes.

Main evidence

Show detailsHide

TAX 327: 3-weekly docetaxel vs mitoxantrone increased median survival from 16.5 to 18.9 months [1]. CHAARTED: adding 6 cycles of docetaxel to ADT increased median survival from 44 to 57.6 months; the benefit was mainly in high-volume disease [2].

Related cancer types

Prostate cancer

Treatment regimens (physicians)

Darolutamide with docetaxel and hormone therapy (ARASENS)

Physician tools and lessons

Localised Prostate Cancer Risk Group Calculator10 cheap steps that save patients' livesBone-modifying agents in cancer: bone metastases, adjuvant use and osteonecrosis of the jawGermline genetic testing in cancer: who, and which genes?

References

3 references
Show all references, 2 with a study cardClose the reference list

Numbers in the text, such as [1], refer to these sources. Sources with a “Study card” button are summarised in the site’s evidence library.

  1. 1
    Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancerTannock IF, de Wit R, Berry WR, et al · N Engl J Med · 2004;351:1502-12
    Study cardDOIPubMed Back to text: 1 2 3
  2. 2
    Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate CancerSweeney CJ, Chen YH, Carducci M, et al · N Engl J Med · 2015;373:737-46
    Study cardDOIPubMed Back to text: 1 2 3
  3. 3
    DOCETAXEL — Prescribing InformationSandoz Inc · FDA label · 2026
    Source Back to text: 1 2

This page is based on reputable scientific sources and was last updated on 28 October 2026. The content of this website is for educational and informational purposes only and does not replace consultation, diagnosis or treatment by a specialist physician. Consult your treating physician about any treatment decision.

Printed from the website; the full and up-to-date version: https://drdabiri.com/en/regimens/docetaxel-prostate/

Related pages

27 October 2026 FOLFOX (mFOLFOX6): dose, schedule and side effects Dose and schedule of mFOLFOX6 (oxaliplatin 85, leucovorin 400, fluorouracil 400 bolus and 2400 as a 46-hour infusion), length of adjuvant treatment, premedication, neuropathy and dose adjustment. 27 October 2026 CAPOX (XELOX): dose, schedule and side effects Dose and schedule of CAPOX or XELOX (oxaliplatin 130 and capecitabine 1000 twice daily, days 1 to 14), length of adjuvant treatment, renal adjustment and side effects. 27 October 2026 FOLFIRI regimen: dose, schedule and side effects Dose and schedule of FOLFIRI (irinotecan 180, leucovorin 400, fluorouracil 400 bolus and 2400 as a 46-hour infusion), diarrhoea control, UGT1A1 and dose adjustment.